First-line avimantamab plus lazertinib shows efficacy in patients with high-risk EGFR-mutant advanced NSCLC
In the MARIPOSA study, a significant improvement in progression-free survival was reported in a subgroup with poor prognostic factors
Eftilagimod alpha plus pembrolizumab shows promise in HNSCC with negative PD-1 expression
In the Cohort B of the TACTI-003 study, the combination therapy led to clinically meaningful response rates in patients with recurrent or metastatic disease
Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Harnessing the power of the gut microbiome in colorectal cancer
Lessons learned about the importance of the gut microbiome composition in immune checkpoint inhibitor therapy response could be crucial in tailoring cancer care
Liver transplantation plus chemotherapy prolongs survival in patients with definitively unresectable colorectal liver metastases
In the TRANSMET trial, a 5-year overall survival benefit was observed in a highly selected patient population
No significant survival benefits reported for perioperative chemoimmunotherapy in resectable G/GEJ cancers
Final results of the KEYNOTE-585 study indicate that the current treatment standard for resectable G/GEJ should remain unchanged
Overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Recent data indicate a role of immunotherapy for tumours with high levels of microsatellite instability, especially in the neoadjuvant setting
Targeting KRAS offers new hope for patients with gastrointestinal cancers
The development of KRAS selective inhibitors promises to expand treatment to a broader population of patients with KRAS-mutated tumours
Cancer Research
The promise of immuno-oncology in the neoadjuvant setting
Recent data from studies show novel pre-operative therapeutic options, but many pending issues need to be addressed
Disappointing early results for niraparib plus dostarlimab in the treatment of relapsed endometrial or ovarian carcinosarcomas
The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination